Patents Assigned to QILU REGOR THERAPEUTICS INC.
  • CDK INHIBITORS
    Publication number: 20240033264
    Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
    Type: Application
    Filed: September 26, 2023
    Publication date: February 1, 2024
    Applicant: QILU REGOR THERAPEUTICS INC.
    Inventors: Zhilong Hu, Hu He, Fei Zhang, Wenge Zhong, Xiaotian Zhu
  • GLP-1R agonists and uses thereof
    Patent number: 11591321
    Abstract: The present disclosure provides compounds of Formula (III) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: February 28, 2023
    Assignee: QILU REGOR THERAPEUTICS INC.
    Inventors: Wenge Zhong, Wei Guo
  • GLP-1R agonists and uses thereof
    Patent number: 10954221
    Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: March 23, 2021
    Assignee: QILU REGOR THERAPEUTICS INC.
    Inventors: Wenge Zhong, Wei Guo
  • GLP-1R agonists and uses thereof
    Patent number: 10844049
    Abstract: The invention described herein provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 24, 2020
    Assignee: QILU REGOR THERAPEUTICS INC.
    Inventor: Wenge Zhong
  • GLP-1R AGONISTS AND USES THEREOF
    Publication number: 20200325121
    Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 15, 2020
    Applicants: QILU REGOR THERAPEUTICS INC., QILU REGOR THERAPEUTICS INC.
    Inventors: Wenge Zhong, Wei Guo